119 related articles for article (PubMed ID: 27665287)
21. Respiratory syncytial virus prophylaxis in Down syndrome: a prospective cohort study.
Yi H; Lanctôt KL; Bont L; Bloemers BL; Weijerman M; Broers C; Li A; Kiss A; Mitchell I; Paes B;
Pediatrics; 2014 Jun; 133(6):1031-7. PubMed ID: 24799541
[TBL] [Abstract][Full Text] [Related]
22. Use of palivizumab in Germany: data from 2002-2007.
Simon A; Nowak H; Sterz R
Klin Padiatr; 2011 Sep; 223(5):292-8. PubMed ID: 21509705
[TBL] [Abstract][Full Text] [Related]
23. Survey of pediatric ward hospitalization due to respiratory syncytial virus infection after the introduction of palivizumab to high-risk infants in Japan.
Kusuda S; Takahashi N; Saitoh T; Terai M; Kaneda H; Kato Y; Ohashi A; Watabe S; Joh-o K; Hirai K
Pediatr Int; 2011 Jun; 53(3):368-73. PubMed ID: 20854284
[TBL] [Abstract][Full Text] [Related]
24. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants.
Blanken MO; Rovers MM; Molenaar JM; Winkler-Seinstra PL; Meijer A; Kimpen JL; Bont L;
N Engl J Med; 2013 May; 368(19):1791-9. PubMed ID: 23656644
[TBL] [Abstract][Full Text] [Related]
25. Palivizumab prophylaxis and hospitalization for respiratory syncytial virus disease in the Stockholm infant population, 1999 through 2002.
Henckel E; Luthander J; Berggren E; Kapadia H; Naver L; Norman M; Bennet R; Eriksson M
Pediatr Infect Dis J; 2004 Jan; 23(1):27-31. PubMed ID: 14743042
[TBL] [Abstract][Full Text] [Related]
26. A review of palivizumab and emerging therapies for respiratory syncytial virus.
Shadman KA; Wald ER
Expert Opin Biol Ther; 2011 Nov; 11(11):1455-67. PubMed ID: 21831008
[TBL] [Abstract][Full Text] [Related]
27. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.
American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn
Pediatrics; 2003 Dec; 112(6 Pt 1):1442-6. PubMed ID: 14654627
[TBL] [Abstract][Full Text] [Related]
28. Respiratory syncytial virus prophylaxis in preterm infants: a cost-effectiveness study from Turkey.
Oncel MY; Mutlu B; Kavurt S; Baş AY; Demirel N; Akyol M; Erdeve O; Dilmen U
Turk J Pediatr; 2012; 54(4):344-51. PubMed ID: 23692714
[TBL] [Abstract][Full Text] [Related]
29. Development and use of palivizumab (Synagis): a passive immunoprophylactic agent for RSV.
Pollack P; Groothuis JR
J Infect Chemother; 2002 Sep; 8(3):201-6. PubMed ID: 12373481
[TBL] [Abstract][Full Text] [Related]
30. Economic evaluation of possible prevention of RSV-related hospitalizations in premature infants in Germany.
Roeckl-Wiedmann I; Liese JG; Grill E; Fischer B; Carr D; Belohradsky BH
Eur J Pediatr; 2003 Apr; 162(4):237-44. PubMed ID: 12647196
[TBL] [Abstract][Full Text] [Related]
31. Effect of palivizumab prophylaxis on subsequent recurrent wheezing in preterm infants.
Yoshihara S; Kusuda S; Mochizuki H; Okada K; Nishima S; Simões EA;
Pediatrics; 2013 Nov; 132(5):811-8. PubMed ID: 24127479
[TBL] [Abstract][Full Text] [Related]
32. Intravenous palivizumab in respiratory syncytial virus infection after hematopoietic stem cell transplant in children.
Torres JP; Tapia LI; Catalán P; De la Maza V; Mejías A
Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28598593
[TBL] [Abstract][Full Text] [Related]
33. Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain.
Sanchez-Luna M; Burgos-Pol R; Oyagüez I; Figueras-Aloy J; Sánchez-Solís M; Martinón-Torres F; Carbonell-Estrany X
BMC Infect Dis; 2017 Oct; 17(1):687. PubMed ID: 29041909
[TBL] [Abstract][Full Text] [Related]
34. Phase 1 evaluation of the respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants.
Boeckh M; Berrey MM; Bowden RA; Crawford SW; Balsley J; Corey L
J Infect Dis; 2001 Aug; 184(3):350-4. PubMed ID: 11443562
[TBL] [Abstract][Full Text] [Related]
35. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection.
;
Pediatrics; 2014 Aug; 134(2):e620-38. PubMed ID: 25070304
[TBL] [Abstract][Full Text] [Related]
36. Prevention of respiratory syncytial virus infection with palivizumab.
Thomas M; Bedford-Russell A; Sharland M
Monaldi Arch Chest Dis; 2000 Aug; 55(4):333-8. PubMed ID: 11057088
[TBL] [Abstract][Full Text] [Related]
37. Adherence to Palivizumab for Respiratory Syncytial Virus Prevention in the Canadian Registry of Palivizumab.
Chan P; Li A; Paes B; Abraha H; Mitchell I; Lanctôt KL;
Pediatr Infect Dis J; 2015 Dec; 34(12):e290-7. PubMed ID: 26780032
[TBL] [Abstract][Full Text] [Related]
38. [Experience of palivizumab in prophylaxis of respiratory syncytial viral infection in premature children with bronchopulmonary dysplasia].
Aliamovskaia GA; Keshinian ES
Vestn Ross Akad Med Nauk; 2012; (12):30, 32-4. PubMed ID: 23530423
[TBL] [Abstract][Full Text] [Related]
39. Palivizumab prophylaxis to prevent respiratory syncytial virus mortality after pediatric bone marrow transplantation: a decision analysis model.
Thomas NJ; Hollenbeak CS; Ceneviva GD; Geskey JM; Young MJ
J Pediatr Hematol Oncol; 2007 Apr; 29(4):227-32. PubMed ID: 17414564
[TBL] [Abstract][Full Text] [Related]
40. Nationwide survey of severe respiratory syncytial virus infection in children who do not meet indications for palivizumab in Japan.
Mori M; Kawashima H; Nakamura H; Nakagawa M; Kusuda S; Saji T; Tsutsumi H; Yokota S; Itoh S;
J Infect Chemother; 2011 Apr; 17(2):254-63. PubMed ID: 20872156
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
